MANUAL ARTICLE REVIEW IS REQUIRED FOR THIS ARTICLE

Manual article review is required for this article

Scientists think that combining navitoclax with ruxolitinib should help individuals with myelofibrosis. In this particular demo fifty percent the individuals have navitoclax and ruxolitinib. One other fifty percent have ruxolitinib as well as a dummy drug (placebo ).(Sorvall Legend RT; Thermo Fisher Scientific) for thirty min. The resulting tissue